

Tissue Specific Induction of p62/*Sqstm1* by Farnesoid X Receptor

Jessica A. Williams¹, Ann M. Thomas¹, Guodong Li^{1,2}, Bo Kong¹, Le Zhan¹, Yuka Inaba³, Wen Xie³, Wen-Xing Ding¹, Grace L. Guo^{1*}

1 Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States of America, **2** Department of Abdominal Surgery, Cancer Treatment Center, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China, **3** Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Abstract

Background: Farnesoid X Receptor (FXR) is a member of the nuclear receptor superfamily and is a ligand-activated transcription factor essential for maintaining liver and intestinal homeostasis. FXR is protective against carcinogenesis and inflammation in liver and intestine as demonstrated by the development of inflammation and tumors in the liver and intestine of FXR knock-out mice. However, mechanisms for the protective effects of FXR are not completely understood. This study reports a novel role of FXR in regulating expression of *Sqstm1*, which encodes for p62 protein. p62 plays an important role in maintaining cellular homeostasis through selective autophagy and activating signal transduction pathways, such as NF- κ B to support cell survival and caspase-8 to initiate apoptosis. FXR regulation of *Sqstm1* may serve as a protective mechanism.

Methods and Results: This study showed that FXR bound to the *Sqstm1* gene in both mouse livers and ileums as determined by chromatin immunoprecipitation. In addition, FXR activation enhanced transcriptional activation of *Sqstm1* *in vitro*. However, wild-type mice treated with GW4064, a synthetic FXR ligand, showed that FXR activation induced mRNA and protein expression of *Sqstm1*/p62 in ileum, but not in liver. Interestingly, FXR-transgenic mice showed induced mRNA expression of *Sqstm1* in both liver and ileum compared to wild-type mice.

Conclusions: Our current study has identified a novel role of FXR in regulating the expression of p62, a key factor in protein degradation and cell signaling. Regulation of p62 by FXR indicates tissue-specific and gene-dosage effects. Furthermore, FXR-mediated induction of p62 may implicate a protective mechanism of FXR.

Citation: Williams JA, Thomas AM, Li G, Kong B, Zhan L, et al. (2012) Tissue Specific Induction of p62/*Sqstm1* by Farnesoid X Receptor. PLoS ONE 7(8): e43961. doi:10.1371/journal.pone.0043961

Editor: Jean-Marc A. Lobaccaro, Clermont Université, France

Received: August 4, 2011; **Accepted:** July 30, 2012; **Published:** August 27, 2012

Copyright: © 2012 Williams et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK081343], the National Center for Research Resources (NCRR) [Grant P20-RR021940] and J.A. Williams was supported by the "Training Program in Environmental Toxicology" [grant 5 T32 ES007079] from the National Institute of Environmental Health Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: gracelguo@yahoo.com

Introduction

Autophagy was strictly thought of as a bulk protein degradation pathway until the discovery that it also performs selective degradation of polyubiquitinated proteins via sequestosome-1 (*Sqstm1*), which encodes for p62 protein. p62 is often found in cellular protein aggregates because it interacts with ubiquitinated proteins through its C-terminal ubiquitin associated (UBA) domain [1]. p62 also interacts with microtubule light chain 3 (LC3), an autophagy protein, via its LC3 interacting region (LIR). In addition to protein aggregates, recent studies indicate that p62 is also recruited to damaged mitochondria via binding to ubiquitinated outer mitochondrial membrane proteins, although this role of p62 in mitophagy is controversial [2,3]. Therefore, p62 may serve as an autophagy receptor for ubiquitinated proteins and damaged mitochondria.

In addition to its role in autophagy, p62 also has a role in signal transduction and aids in a cell's decision to undergo apoptosis or

survival through its organization of signaling complexes in the cytoplasm [1,4,5]. Upon cytokine stimulation, p62 is able to activate the nuclear factor kappa-light chain-enhancer of activated B cells (NF- κ B) pathway [5–7]. Activated NF- κ B induces the expression of pro-survival genes, such as anti-apoptosis and cell proliferation genes. Activated NF- κ B also induces the expression of inflammatory genes such as cytokines, chemokines, and adhesion molecules [8]. In addition, p62 activates nuclear factor erythroid 2-related factor 2 (Nrf2) by binding to kelch-like ECH-associated protein 1 (Keap1), which is important for inducing expression of genes involved in the oxidative stress response [9–11]. Finally, p62 is able to fully activate caspase-8 in the extrinsic apoptosis pathway, which results in the initiation of apoptosis and cell death [4]. Ultimately, p62 helps maintain cellular homeostasis through its participation in autophagy and signal transduction. Therefore, a defect in autophagy can cause an accumulation of damaged organelles and p62-bound protein aggregates or defects in signal transduction, which can lead to tissue injury and disease.

Farnesoid X Receptor (FXR) is a ligand-activated transcription factor and a member of the nuclear receptor superfamily. FXR is highly expressed in liver and intestine [12]. FXR can be activated by bile acids, which are its endogenous ligands [13–15], or by synthetic ligands such as GW4064 [16]. FXR activation is essential in maintaining bile-acid homeostasis via transcriptional regulation of nuclear receptors, bile-acid transporters, and the hormonal fibroblast growth factor *Fgf15/19* [17].

In addition to its function in maintaining bile-acid homeostasis, FXR regulates lipid metabolism [18,19], cholesterol metabolism [20,21], liver regeneration [22], and glucose metabolism [23]. Recent studies also indicate a role for FXR in regulating innate immunity and inflammation [24–27]. Although the exact role of FXR in regulating tissue homeostasis is not clear, FXR deficiency leads to development of various disease states such as hepatocellular carcinoma [28,29], intestinal tumorigenesis [30–32], intestinal inflammation [24,26,33], cholestasis [34], nonalcoholic steatohepatitis (NASH) [35] and gall stone formation [36].

A possible new role for FXR has been revealed through our discovery of a novel binding site within the *Sqstm1* gene in liver and ileum by genome-wide analysis [37]. However, it is unknown whether FXR can functionally regulate expression of the *Sqstm1* gene. If this hypothesis is verified, it may represent a mechanism by which FXR maintains tissue homeostasis and regulates inflammation. Therefore, the purpose of this study was to determine if binding of FXR to the *Sqstm1* gene in the liver and ileum produces a functional binding site capable of inducing transcriptional activation of the *Sqstm1* gene. Our findings indicate that FXR binds to the *Sqstm1* gene in both liver and ileum. However, activation of FXR only induces *Sqstm1* expression in the ileum but not in the liver, suggesting complex regulation of *Sqstm1* gene transcription in a tissue-specific manner. In addition, FXR-mediated induction of p62 may be a potential protective mechanism of FXR.

Materials and Methods

Animals and Treatment

Animals for Chromatin Immunoprecipitation (ChIP) studies were treated as previously described [37]. Briefly, 10-week old FXR knockout (FXR^{-/-}) and wild-type (WT) mice with a C57BL/6 background were fasted overnight and then given a one-time treatment of vehicle (PBS with 1% Tween-20 and 1% methylcellulose) or GW4064 (75 mg/kg) by oral gavage for four hours before harvesting of their livers or two hours before harvesting of their ileums for ChIP-Seq analysis. For mRNA and protein level studies, ten to twelve-week old FXR^{-/-} and WT mice were fasted overnight and received a one-time treatment of GW4064 (150 mg/kg) or vehicle by oral gavage for either 4 or 16 hours before harvesting of their livers and ileums for RNA and protein extraction. The VP-FXR transgenic mice were generated as previously described [38]. Briefly, constitutively active FXR was overexpressed in the liver and intestine using the tetracycline-inducible transgenic system. VP-FXR was generated by fusing the VP-16 transactivation domain from the herpes simplex virus to the 5' end of the FXR cDNA. FXR^{-/-} mice were generated as previously described [34]. All animal protocols were approved by the University of Kansas Medical Center Animal Care and Use Committee (protocol number 2010-1947), and the mice were cared for according to standard guidance. All efforts were made to minimize suffering.

ChIP-Seq

Chromatin immunoprecipitation (ChIP) followed by massive parallel sequencing (ChIP-seq) analysis was performed as previously reported [37]. Briefly, cross-linked sonicated genomic DNA extracted from ten week-old fasted WT and FXR^{-/-} male mouse livers or ileums gavaged with vehicle or GW4064 for 2 hours (ileum) or 4 hours (liver) were immunoprecipitated with antibody against FXR. Immunoprecipitated DNA fragments were then prepared for massive parallel sequencing analysis as previously described [37]. Enriched intervals, referred to as peak values, were identified when a given genomic region containing more than one enriched interval overlapping by at least one base pair appeared more than 20 times. Histograms of FXR binding to the *Sqstm1* gene in liver and ileum were generated by loading sequencing BAR files into Affymetrix Integrated Genome Browser (IGB) [39].

ChIP-quantitative PCR (ChIP-qPCR)

ChIP was performed as previously described [37]. Briefly, ChIP assay was performed using anti-FXR antibody (H-130, Santa Cruz, CA), and immunoprecipitated DNA was analyzed by quantitative PCR (qPCR) using SYBR Green chemistry (Fermentas, Glen Burnie, Maryland). QPCR was performed to amplify FXR binding sites located in the *Nr0b2* and *Ostf* genes, which are positive control regions for FXR binding, as well as for the novel FXR binding site in the *Sqstm1* gene. A novel FXR binding site identified by ChIP-seq analysis was located 13.1 kb downstream of the *Sqstm1* transcription start site (TSS). This site was amplified by ChIP qPCR analysis using primers: *Nr0b2* 3' binding site F: 5'-CAGTCCACGCCCTCAGCCC-3' and R: 5'-GGCAGGAGGAGGTCTGAAAGC-3', *Ostf* F: 5'-CCGCAATGGCAGATCATAC-3' and R: 5'-GTGAATGACCCCACGAATG-3', and *Sqstm1* F: 5'-CACTGCACATGTGTGTTTCTGTGT-3' and R: 5'-AGGGTGTGGACAGTGTGTAAGACA-3'. ChIP-qPCR results were normalized to input and expressed as fold over IgG negative controls.

RNA Isolation and Real-Time qPCR

RNA was isolated using TRI Reagent (Ambion, Applied Biosystems, Austin, TX) according to the manufacturer's instructions, and RNA concentration was determined by spectrophotometry. cDNA was generated using standard RT-PCR protocols, and qPCR was performed using SYBR Green chemistry. The following primers were used for Real-Time qPCR: *Shp* F: 5'-CGATCCTCTTCAACCCAGATG-3' and R: 5'-AGGGCTC-CAAGCATTACACA-3', *Ibapb* F: 5'-GGTCTTCCAGGAGACGTGAT-3' and R: 5'-ACATTCTTTGCCAATGGTGA-3', and *Sqstm1/p62* F: 5'-AGAATGTGGGGAGAGTGTG-3' and R: 5'-TCGTCTCCTCCTGAGCAGTT-3'. Real-time qPCR results were normalized to 18 s and expressed as fold over WT vehicle control.

Construction of Plasmids

A 2 kb region of the *Sqstm1/p62* gene containing a FXR response element, which is an inverted repeat separated by one nucleotide (IR1), was cloned into a PGL4-TK luciferase vector. This IR1 was located 13.1 kb downstream of the *Sqstm1/p62* gene TSS. The cloned construct was confirmed by DNA sequencing, and the new plasmid was named PGL4-p62-TK luciferase vector.

This IR1 was mutated in the PGL4-p62-TK vector using a QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions utilizing the following primers: F:5'-GCAATCCTACGTTGCCCC-




Figure 1. ChIP-seq results for FXR binding to *Sqstm1*. 10-week old WT mice were fasted overnight and then given a one-time treatment of vehicle or GW4064 (75 mg/kg) for four hours (liver) or two hours (ileum). Cross-linked sonicated genomic DNA extracted from livers and ileums were immunoprecipitated with antibody against FXR. ChIP-seq analysis revealed that FXR binds to two locations within the 3' end of the *Sqstm1* gene in the liver and ileum as shown by two binding peaks located 13.1 kb and 15.8 kb downstream from the TSS of *Sqstm1* on chromosome 11. These peaks represent binding abundance. The highest binding peak in the intestine is represented by a peak value of 815, and the highest binding peak in the liver is represented by a peak value of 755. The 13.1 kb site contains a classical IR1, and the 15.8 kb site does not. The location within chromosome 11 is indicated for the IR1 at the 13.1 kb binding site along with the IR1 sequence. N = 3–4 mouse livers or ileums per group. doi:10.1371/journal.pone.0043961.g001

CAAGTTCACTGATGTGGTGTTCAAAAGTTGTC-3' and R: 5'-GACAACCTTTGAACACCACATCAGTGAACCTGGGGC-CAACGTAGGATTGC-3'. These primers generated an IR1 mutant by changing the IR1 sequence 5'-CGGTCACTGACCT-3' to the mutant sequence 5'-AGTTCACTGATGT-3'. The mutated base pairs are underlined in the original sequence. The mutation was confirmed by DNA sequencing, and the mutated plasmid was named p62-M.

Cell Culture, Transient Transfection, and Luciferase Reporter Gene Assay

HepG2 cells, purchased from the American Type Culture Collection (Manassas, VA), were cultured in DMEM supplemented with 10% fetal bovine serum (Omega Scientific, Tarzana, CA) and 1% penicillin/streptomycin in a 5% CO₂ humidified atmosphere at 37°C. Cells were plated at a density of 5,000 cells per well in 200 μ L medium in a 96-well plate and incubated overnight. Transient transfection was performed as previously described [40]. Briefly, cells were transfected with 0.2 μ g plasmid per well containing either PGL4-p62-TK or p62-M along with human FXR, human RXR α and PCMV-renilla luciferase vector (Promega, Madison, WI) using TurboFect *in vitro* transfection reagent (Fermentas, Glen Burnie, Maryland) according to the manufacturer's instructions. The previously described PGL4-Shp-TK plasmid [40] was used as a positive control for FXR activation. Six hours after transfection, medium was changed and cells were treated with 1 μ M

GW4064 or 0.1% DMSO as a control. Thirty six to forty eight hours later, firefly and renilla luciferase activities were measured using a Dual-Glo Luciferase Assay kit (Promega, Madison, WI). Firefly luciferase activity of each well was normalized as a ratio to that of renilla luciferase and expressed as fold over PGL4-TK empty vector control.

Western Blot

Cytoplasmic extracts from FXR $-/-$ and WT mouse liver and ileum were isolated using a NE-PER kit (Thermo Scientific, Fremont, CA) according to the manufacturer's instructions. Protein concentration was measured using BCA assay (Thermo Scientific, Fremont, CA). Western Blot was performed using 20 μ g of protein separated on a 10% SDS/PAGE gel and transferred to a 0.45 μ m PVDF membrane (Millipore, Billerica, MA). The membrane was blocked with 5% non-fat milk in TBS before adding p62 antibody (1:1000, Abnova, Walnut, CA). A chloroquine-treated HeLa cell lysate sample was used as a positive control for p62 labeling (molecular weight 62 kDa), and β -Actin (molecular weight 42 kDa) was used as a loading control. Band density was determined using ImageJ software.

Statistics

A student's *t*-test was used to determine statistical significance for samples that demonstrated equal variance. A Mann-Whitney Rank Sum test was used to determine statistical significance for samples that did not demonstrate equal variance. A *p*-value of




Figure 2. CHIP-qPCR results to confirm FXR binding to *Sqstm1*/p62 in liver and ileum. 10 to 12-week old FXR^{-/-} and WT mice were fasted overnight and then given a one-time treatment of vehicle or GW4064 (75 mg/kg) for four hours (liver) or two hours (ileum). ChIP assay was performed using an antibody against FXR, and immunoprecipitated DNA was analyzed by qPCR. A: Vehicle-treated WT mice showed binding of FXR to *Sqstm1*/p62 in both liver (126-fold) and ileum (18-fold) when compared to IgG controls. This binding was reduced to IgG control levels in liver and ileum for vehicle-treated FXR^{-/-} mice. *Ostβ* was used as a positive control for FXR binding in both liver and ileum. In the liver, there was a 36-fold increase in binding to *Ostβ* compared to IgG controls, and there was a 32-fold increase for binding to *Ostβ* in the ileum compared to IgG controls. This binding was reduced to IgG control levels in liver and ileum of vehicle-control treated FXR^{-/-} mice (*indicates p<0.05, N=3 WT and 4 FXR^{-/-} mouse livers or ileums). B: Treatment of WT mice with the FXR agonist GW4064 increased FXR binding to the *Sqstm1*/p62 gene in both mouse liver and ileum. In liver, there was a 40-fold increase in FXR binding to the *Sqstm1*/p62 gene. The FXR target gene *Nr0b2*/Shp was used as a positive control for liver and showed a 2.5-fold increase after GW4064 treatment. In ileum, there was a 10-fold increase in FXR binding to *Sqstm1*/p62 with GW4064 treatment. The FXR target gene *Ostβ* was used as a positive control for ileum and showed a 4-fold increase after GW4064 treatment (*indicates p<0.05, **indicates p<0.01, N=4 mouse livers or ileums per group). doi:10.1371/journal.pone.0043961.g002

<0.05 was considered statistically significant. A p-value of <0.05 is indicated by * and a p-value of <0.01 is indicated by **.

Results

FXR Binding to the *Sqstm1* Gene in Mouse Liver and Ileum

Binding of FXR to two regions at the 3' end of the *Sqstm1* gene in the liver and ileum was discovered by our genome-wide ChIP-seq analysis [37]. These two FXR binding sites were located 13.1 and 15.8 kb downstream of the *Sqstm1* TSS on chromosome 11. Abundance of FXR binding to novel and known target genes in the liver and ileum in ChIP-seq results were interpreted by a binding peak value. The peak value of FXR binding to the *Sqstm1* gene at the 13.1 kb site was 755 in liver and 815 in ileum (Figure 1). The peak value of FXR binding to the *Sqstm1* gene at the 15.8 kb site was 330 in liver and 500 in ileum (Figure 1). Binding of FXR to the 13.1 kb site of the *Sqstm1* gene represented one of the highest peak values detected by ChIP-seq analysis, and it is relatively high compared to FXR binding to other known FXR target genes. For example, the peak value of FXR binding to the *Nr0b2* gene encoding small heterodimer partner (Shp) was 498, and the

peak value of FXR binding to the *Ostβ* gene encoding organic solute transporter β (*Ostβ*) was 572 [37]. Furthermore, sequence analysis of the 13.1 kb FXR binding site within the *Sqstm1* gene by NUBIScan [41] revealed the presence of a classical IR1. The chromosomal location of this IR1 and its sequence are shown in Figure 1. The 15.8 kb binding site did not have an IR1 present according to NUBIScan [41]. Therefore, the 13.1 kb site was further analyzed as a functional FXR binding site.

The binding results from ChIP-seq were confirmed by ChIP-qPCR as shown in Figure 2. Vehicle-treated WT mice showed binding of FXR to *Sqstm1*/p62 in both liver (126-fold) and ileum (18-fold) when compared to IgG controls. This binding was reduced to IgG control levels in liver and ileum for vehicle-treated FXR^{-/-} mice (Figure 2A). *Ostβ* is a known FXR target gene and was used as a positive control for FXR binding in both liver and ileum with a 36-fold and a 32-fold increase in binding in the liver and ileum, respectively, compared to IgG controls (Figure 2A). This binding was also reduced to IgG control levels in liver and ileum of vehicle-control treated FXR^{-/-} mice (Figure 2A). Furthermore, treatment of WT mice with a FXR synthetic agonist, GW4064, increased FXR binding to the *Sqstm1* gene in both mouse liver and ileum (Figure 2B). In liver, there was an increase in FXR binding to the *Sqstm1*/




Figure 3. Activation of FXR enhanced *Sqstm1/p62* transcriptional activation as revealed by luciferase assay. HepG2 cells were transfected with plasmid DNA containing either the PGL4-Shp-TK plasmid as a positive control or the plasmid DNA containing the 2 kb fragment of *Sqstm1/p62* with the FXR IR1 (A) or the mutant IR1 (p62-M) (B). These plasmids were transfected along with human FXR, human RXR α and PCMV-renilla luciferase vector before the cells were treated with 1 μ M GW4064 or 0.1% DMSO control for 36 to 48 hours. Firefly luciferase activity of each well was normalized as a ratio to that of renilla luciferase and expressed as fold over PGL4-TK empty vector control. The FXR target gene *Shp* was used as a positive control (**indicates $p < 0.01$, $N = 6$ wells per treatment).

doi:10.1371/journal.pone.0043961.g003

p62 gene (40-fold, $p < 0.05$) and to the *Nr0b2/Shp* gene (2.5 fold, $p < 0.01$) with GW4064 treatment for 4 hours. In ileum, 2-hour GW4064 treatment resulted in an increase in FXR binding to both *Sqstm1/p62* and *Ost β* genes (10-fold and 4-fold, respectively).

Activation of FXR Enhances Transcriptional Activation of *Sqstm1* as Revealed by the Luciferase Reporter Gene Assay

A luciferase reporter assay was performed to determine if FXR binding to the *Sqstm1/p62* gene was functional in enhancing transcription. Activation of FXR by GW4064 increased the luciferase activity of *p62* 3 to 7 fold ($p < 0.01$, Figures 3A and 3B) when driven by an IR1 FXR response element (5'-CGGTCACGACCT-3') found 13.1 kb downstream of the *Sqstm1/p62* gene TSS compared to PGL4-TK vector control (Figure 3A). In addition, mutation of this FXR response element (p62-M, 5'-AGTTCACGATGT-3') reduced luciferase activity to levels similar to the PGL4-TK vector control (Figure 3B). As a positive control, activation of FXR by GW4064 significantly enhanced luciferase activity approximately 3 to 4 fold ($p < 0.01$) when driven by a FXR response element identified in the *Nr0b2/Shp* gene regulatory region (Figures 3A and 3B).

Activation of FXR Induces mRNA Expression of *Sqstm1* in Ileum but not in Liver

Binding of FXR to the *Sqstm1* gene does not guarantee activation of the gene's transcription because many factors are involved in gene transcriptional activation. Therefore, *Sqstm1/p62* mRNA expression levels were determined following FXR activation using *Nr0b2* or *Fabp6* as positive controls. *Fabp6* is the gene encoding for ileum bile acid binding protein (Ibap). *Shp* is a classical target gene of FXR in the liver, and *Ibap* is a direct target gene of FXR in the ileum. A significant GW4064-mediated induction of *Shp* mRNA was observed in both the 4- (2.8-fold) and 16-hour (2.4-fold) treatment groups for WT mouse livers ($P < 0.01$), as shown in Figure 4A. However, no induction of *Sqstm1/p62* mRNA was seen for either time point in WT mouse livers (Figure 4A).

In contrast to results seen in the liver, a GW4064-mediated induction of both *Ibap* and *Sqstm1/p62* mRNA was observed in the 4- and 16-hour GW4064 treatment groups for WT mouse ileum when compared to vehicle controls (Figure 4B). Treatment with GW4064 resulted in a significant 2.5 and 6.9-fold induction of *Ibap* ($p < 0.05$) and a 1.6 and 1.7-fold induction in *Sqstm1/p62* mRNA in the 4 and 16-hour treatment groups in WT mouse ileum, respectively. Only the 4-hour GW4064 treatment group induction of *Sqstm1/p62* mRNA was statistically significant ($p < 0.05$).

We then used FXR $-/-$ mice to confirm that the GW4064-mediated induction of *Sqstm1* gene expression was due to FXR activation. As shown in Figure 4A, a significant decrease in baseline *Shp* expression levels in liver was seen in both vehicle- and GW4064-treated FXR $-/-$ mice for the 4- and 16-hour treatment groups when compared to WT vehicle controls ($p < 0.01$). However, FXR deficiency did not seem to affect *Sqstm1/p62* baseline expression in mouse livers. For mouse ileums, a significant decrease in baseline *Ibap* expression was seen in both vehicle- and GW4064-treated FXR $-/-$ mice in the 4- and 16-hour treatment groups when compared to WT vehicle controls ($p < 0.01$, Figure 4B). In addition, FXR $-/-$ mice showed a baseline decrease in *Sqstm1/p62* expression in ileum in both 4- and 16-hour GW4064 treatment groups, but this finding was only statistically significant for the 16-hour treatment group ($p < 0.05$, Figure 4B).

Protein Expression of *p62* in Mouse Liver and Ileum

It is known that *p62* is expressed in intestinal epithelia [42]. After we observed induction of *Sqstm1/p62* mRNA by FXR activation in ileum, we determined whether increased mRNA levels translated into protein induction. As shown in Figure 5, GW4064 treatment significantly increased *p62* protein expression 2-fold ($p < 0.05$) over vehicle controls in mouse ileum. Furthermore, the GW4064-mediated induction of *p62* protein expression was abolished in FXR $-/-$ mouse ileums. However, there was no effect of GW4064 treatment on *p62* protein expression in mouse liver.

mRNA Expression of *Sqstm1* in FXR Transgenic Mouse Liver and Ileum

We used VP-FXR transgenic mice to determine whether genetically constitutive activation of FXR could also regulate the expression of *Sqstm1/p62*. As shown in Figure 6, *Sqstm1/p62* mRNA expression was significantly increased in both liver and ileum from VP-FXR transgenic mice when compared to WT controls ($p < 0.05$). *Shp* and *Ibap* were used as positive controls and were also significantly increased in VP-FXR transgenic mouse




Figure 4. Relative mRNA expression levels of *Sqstm1*/p62 determined by quantitative PCR in WT and FXR^{-/-} mouse liver (A) and ileum (B) after treatment with GW4064 for 4 or 16 hours. Ten to twelve week-old WT and FXR^{-/-} mice were fasted overnight and received a one-time treatment of GW4064 (150 mg/kg) or vehicle for either 4 or 16 hours before removal of their livers and ileums for RNA isolation. *Sqstm1*/p62 mRNA expression was induced in WT ileum upon FXR activation with GW4064 but not in liver. In addition, basal expression levels of *Sqstm1*/p62 decreased in FXR^{-/-} mice in ileum but not in liver. FXR target genes Shp and Ibabp were used as positive controls for liver and ileum, respectively. Expression of Shp and Ibabp was induced by GW4064 treatment in WT mice, and basal expression of these target genes decreased in FXR^{-/-} mice as expected. Real-time qPCR results were normalized to 18 s and expressed as fold over WT vehicle control (*indicates $p < 0.05$ and **indicates $p < 0.01$, $N = 5$ for WT and $N = 4$ for FXR^{-/-} mouse livers or ileums). doi:10.1371/journal.pone.0043961.g004

liver and ileum, respectively, when compared to WT mice ($p < 0.05$).

Discussion

p62 is the protein encoded by the *Sqstm1* gene and has important cellular functions. In addition to the well-known role of p62 in facilitating selective autophagy, p62 also activates NF- κ B [5–7], which is well known for its regulation of genes needed to promote cell survival and inflammation. In addition, p62 activates apoptosis to promote cell death [4] and activates the Nrf2 pathway to respond to oxidative stress [9–11].

FXR is a nuclear receptor suspected to have a role in the regulation of homeostasis in both liver and intestine. In the current study, we revealed that *Sqstm1* is a *bona fide* FXR target gene by showing a novel FXR binding site located within the *Sqstm1* gene in mouse liver and ileum using ChIP-seq analysis (Figure 1). In addition, treatment with the synthetic ligand of FXR, GW4064, increased binding of FXR to this novel target gene in both liver and ileum, and this binding was significantly reduced in FXR^{-/-} mice (Figure 2). Furthermore, binding of FXR to the *Sqstm1* gene regulatory region led to increased transcriptional activation as confirmed by luciferase reporter assay, and this transcriptional activation was abolished when the IR1 FXR response element was mutated (Figure 3). However, it appears that induction of *Sqstm1* is

tissue-specific because mice treated with GW4064 to activate FXR only had an induced expression of *Sqstm1* in the ileum but not in the liver (Figure 4). The results from this study provide a potential mechanism by which FXR regulates the inflammatory response and/or promotes cellular homeostasis by inducing transcription of p62.

The tissue-specific induction of *Sqstm1*/p62 mRNA, despite the fact that FXR binds to a gene regulatory region of *Sqstm1* in both liver and ileum, is an intriguing observation. This suggests that p62 is regulated by multiple transcription factors. For example, another known transcriptional regulator of p62 is Nrf2, which is important for regulating the oxidative stress response [9]. Therefore, the presence and/or balance of these various transcription factors, and possible inhibitory factors, that regulate p62 expression may determine whether FXR binding will be translated into transcriptional activation of the *Sqstm1* gene. In addition, the fact that *Sqstm1*/p62 expression is not induced in the liver with FXR activation could be due to higher basal expression of *Sqstm1*/p62 in the liver than in the ileum.

Even though induction of *Sqstm1* mRNA expression and p62 protein expression was only seen in mouse ileum and not in mouse liver after FXR activation (Figures 4 and 5), there was an increase in *Sqstm1* mRNA expression in both the liver and ileum of the VP-FXR transgenic mice (Figure 6). This increase in *Sqstm1* mRNA




Figure 5. Western blot for p62 in mouse liver and ileum (A) with band density normalized to β -actin (B). WT and FXR^{-/-} mice were treated with GW4064 (150 mg/kg) or vehicle for 16 hours before removal of their livers and ileums. Cytosolic extracts were used to determine p62 protein expression by western blot (A), and band density values were normalized to β -Actin (B). Protein expression of p62 increased in ileum upon FXR activation, but activation of FXR had no effect on p62 protein expression in the liver. The samples used for the blot shown are pooled liver and ileum samples from three mice. The error bars in the graph indicate results from the individual mouse livers and ileums run on separate blots, which are not shown. Band density was determined using ImageJ software (*indicates $p < 0.05$, $N = 3$ mouse livers or ileums, + represents chloroquine treatment, which is a positive control for p62 expression). doi:10.1371/journal.pone.0043961.g005

expression in the liver of VP-FXR transgenic mice could be due to the presence of constitutively active FXR, which is not present in WT mice treated with GW4064 to activate FXR. Assuming the inability of FXR activation to induce *Sqstm1* expression in the liver is due to the presence of a co-repressor or inhibitory transcription factor, then constitutively active FXR in the transgenic mice might be strong enough to remove or override a competing transcription factor or co-repressor bound to the *Sqstm1* promoter, and therefore, promotes transcription of the gene.

The specific IR1 sequence found in mouse is not conserved in human. However, there are several IR1 sites located within this downstream region on Chromosome 5 in human according to analysis by NUBIScan [41]. FXR may regulate *Sqstm1* gene expression in human by binding to one of these IR1 response elements. Furthermore, the ileum-specific regulation of *Sqstm1*/p62 by FXR may have an implication in intestinal diseases. FXR deficiency has been shown to cause intestinal injury and disease such as inflammation [24,26,33] and tumorigenesis [30–32]. In addition, FXR has been shown to play a role in maintaining intestinal epithelial cell proliferation to protect against tumorigenesis [31,32]. Therefore, it is possible that FXR regulates the expression of the *Sqstm1* gene in the ileum in order to mediate selective autophagy or signal transduction to maintain cellular




Figure 6. p62 mRNA expression in VP-FXR transgenic mouse liver (A) and ileum (B). Expression of *Sqstm1*/p62 mRNA was determined in VP-FXR transgenic mouse livers and ileums. Ibapb and Shp were used as positive controls for ileum and liver, respectively. Expression of *Sqstm1*/p62 mRNA was induced in both VP-FXR transgenic mouse liver and ileum compared to WT controls. Expression of positive control Shp and Ibapb mRNA was induced in transgenic mouse liver and ileum, respectively, when compared to WT controls (*indicates $p < 0.05$, **indicates $p < 0.01$, $N = 5$ mouse livers or ileums). doi:10.1371/journal.pone.0043961.g006

homeostasis, regulate the inflammatory response, and/or conduct tissue repair. If FXR is indeed regulating *Sqstm1*/p62 expression for these processes, then tissue-specific drug development of a synthetic activator of FXR in the intestine could be beneficial for treating or preventing intestinal diseases. This tissue-specific role of FXR in *Sqstm1* gene regulation is a novel finding and subsequent studies will further investigate the role of FXR in the regulation of *Sqstm1*/p62.

In conclusion, it is known that both p62 and FXR have beneficial effects in maintaining cellular homeostasis and preventing disease. We have shown that FXR transcriptionally regulates p62 expression in the intestine. Understanding the role of FXR's regulation of p62 may further advance our understanding of p62 function, as well as the underlying molecular mechanism of FXR targeted pathways.

Author Contributions

Conceived and designed the experiments: GLG JAW WXD. Performed the experiments: JAW AMT GL BK LZ YI WX. Analyzed the data: JAW AMT GL WX. Wrote the paper: JAW GL AMT GLG WXD WX.

References

- Moscat J, Diaz-Meco MT, Wooten MW (2007) Signal integration and diversification through the p62 scaffold protein. *Trends Biochem Sci* 32: 95–100.
- Ding WX, Ni HM, Li M, Liao Y, Chen X, et al. (2010) Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. *J Biol Chem* 285: 27879–27890.
- Narendra D, Kane LA, Hauser DN, Fearnley IM, Youle RJ (2010) p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. *Autophagy* 6: 1090–1106.
- Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, et al. (2009) Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. *Cell* 137: 721–735.
- Sanz L, Diaz-Meco MT, Nakano H, Moscat J (2000) The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. *EMBO J* 19: 1576–1586.
- Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, et al. (2008) The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. *Cancer Cell* 13: 343–354.
- Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J (1999) The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. *EMBO J* 18: 3044–3053.
- Perkins ND (2000) The Rel/NF-kappa B family: friend and foe. *Trends Biochem Sci* 25: 434–441.
- Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, et al. (2010) p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. *J Biol Chem* 285: 22576–22591.
- Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, et al. (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol* 12: 213–223.
- Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, et al. (2010) A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. *Mol Cell Biol* 30: 3275–3285.
- Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, et al. (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell* 81: 687–693.
- Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, et al. (1999) Identification of a nuclear receptor for bile acids. *Science* 284: 1362–1365.
- Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. *Science* 284: 1365–1368.
- Wang H, Chen J, Hollister K, Sowers LC, Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol Cell* 3: 543–553.
- Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. *J Med Chem* 43: 2971–2974.
- Zhu Y, Li F, Guo GL (2011) Tissue-specific function of farnesoid X receptor in liver and intestine. *Pharmacol Res* 63: 259–265.
- Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, et al. (2003) Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. *Gastroenterology* 125: 544–555.
- Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, et al. (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. *J Clin Invest* 113: 1408–1418.
- Kalaany NY, Mangelsdorf DJ (2006) LXRS and FXR: the yin and yang of cholesterol and fat metabolism. *Annu Rev Physiol* 68: 159–191.
- Lambert G, Amar MJ, Guo G, Brewer HB, Jr., Gonzalez FJ, et al. (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. *J Biol Chem* 278: 2563–2570.
- Huang W, Ma K, Zhang J, Qatanani M, Cuvillier J, et al. (2006) Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. *Science* 312: 233–236.
- Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, et al. (2004) Glucose regulates the expression of the farnesoid X receptor in liver. *Diabetes* 53: 890–898.
- Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, et al. (2011) Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. *Gut* 60: 463–472.
- Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C (2003) Repression of farnesoid X receptor during the acute phase response. *J Biol Chem* 278: 8988–8995.
- Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. *J Immunol* 183: 6251–6261.
- Wang YD, Chen WD, Wang M, Yu D, Forman BM, et al. (2008) Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. *Hepatology* 48: 1632–1643.
- Kim I, Morimura K, Shah Y, Yang Q, Ward JM, et al. (2007) Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. *Carcinogenesis* 28: 940–946.
- Yang F, Huang X, Yi T, Yen Y, Moore DD, et al. (2007) Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. *Cancer Res* 67: 863–867.
- De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, et al. (2004) The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. *Dig Dis Sci* 49: 982–989.
- Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, et al. (2009) Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. *J Pharmacol Exp Ther* 328: 469–477.
- Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A (2008) Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. *Cancer Res* 68: 9589–9594.
- Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, et al. (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. *Proc Natl Acad Sci U S A* 103: 3920–3925.
- Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, et al. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. *Cell* 102: 731–744.
- Kong B, Luyendyk JP, Tawfik O, Guo GL (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. *J Pharmacol Exp Ther* 328: 116–122.
- Moschetta A, Bookout AL, Mangelsdorf DJ (2004) Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. *Nat Med* 10: 1352–1358.
- Thomas AM, Hart SN, Kong B, Fang J, Zhong XB, et al. (2010) Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. *Hepatology* 51: 1410–1419.
- Li G, Thomas AM, Williams JA, Kong B, Liu J, et al. (2012) Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. *PLoS One* 7: e35895.
- Nicol JW, Helt GA, Blanchard SG, Jr., Raja A, Loraine AE (2009) The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. *Bioinformatics* 25: 2730–2731.
- Li G, Thomas AM, Hart SN, Zhong X, Wu D, et al. (2010) Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner. *Mol Endocrinol* 24: 1404–1412.
- Podvinec M, Kaufmann MR, Handschin C, Meyer UA (2002) NUBIScan, an in silico approach for prediction of nuclear receptor response elements. *Mol Endocrinol* 16: 1269–1279.
- Maynard AA, Dvorak K, Khailova L, Dobrenen H, Arganbright KM, et al. (2010) Epidermal growth factor reduces autophagy in intestinal epithelium and in the rat model of necrotizing enterocolitis. *Am J Physiol Gastrointest Liver Physiol* 299: G614–G622.